Delcath to test drug delivery system for liver cancer
This article was originally published in Clinica
Executive Summary
Delcath Systems plans to start a pivotal trial in the US for its non-surgical, minimally invasive drug delivery system for the treatment of liver cancer, pending budget and review board approval from the New York University School of Medicine.